Total Revenue: $15.4B Founded Year: 1916 Total Employees: 29,900 Headquarters: Melbourne, Australia Market Cap: $47.64B Stock Exchange: ASX CSL is a global biotechnology company focused on developing and delivering plasma-derived therapies, vaccines, and specialty medicines, operating through key segments like CSL Behring, CSL Seqirus, and CSL Vifor collectively addressing rare diseases, immunology, and infectious diseases
Protecting your hair if you restart or change GLP-1 medications Switching from one GLP-1 medication to another, or restarting after a break, carries a theoretical risk of triggering another round of telogen effluvium, particularly if the new medication or restart leads to another phase of rapid weight loss
Want more nutrition tips
GLP-1 medications are designed to act on pathways involved in: Slower digestion and fullness cues Insulin response after meals Appetite signaling Blood sugar regulation Common GLP-1 medications include: Semaglutide Liraglutide Dulaglutide Tirzepatide A licensed provider may consider GLP-1 therapy for eligible patients with goals related to: Weight loss Prediabetes Type 2 diabetes Appetite control Metabolic support Your response depends on genetics, starting health, dosage, lifestyle habits, and how long GLP-1 stays active in your system
This usually normalizes into comfortable reduced appetite within two to three weeks
Some of you might say you dont want these drugs, but the environment is not going to change back to the 1970s within the next week
